Malin (MLLNF) Other Long Term Assets: $142.30 Mil (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MLLNF Malin Corporation PLC MLLNF
17 GF Score
Price $6.40
View Full Analysis

What is Malin Other Long Term Assets?

Malin MLLNF 17 Other Long Term Assets is $142.30 Mil as of Dec. 2024. GuruFocus rates MLLNF with a GF Score™ of 17/100.

Malin's other long-term assets for the quarter that ended in Dec. 2024 was $142.30 Mil.

Malin's quarterly other long-term assets increased from Dec. 2023 ($88.01 Mil) to Jun. 2024 ($99.57 Mil) and increased from Jun. 2024 ($99.57 Mil) to Dec. 2024 ($142.30 Mil).

Malin's annual other long-term assets declined from Dec. 2022 ($119.39 Mil) to Dec. 2023 ($88.01 Mil) but then increased from Dec. 2023 ($88.01 Mil) to Dec. 2024 ($142.30 Mil).

Malin Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for Malin's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Malin Other Long Term Assets Chart

Malin Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Long Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 344.16 214.80 119.39 88.01 142.30

Malin Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 119.39 74.54 88.01 99.57 142.30
MLLNF
17GF Score
Malin Corporation PLC MLLNF
Other Long Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Malin Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of $142.30 Mil mean?
Malin (MLLNF) has a Other Long Term Assets of $142.30 Mil as of Dec. 2024. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Malin and its competitors.
Is Malin's Other Long Term Assets too high?
Malin's current Other Long Term Assets is $142.30 Mil. Overall, Malin has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Malin's Other Long Term Assets compare to ZTS and UTHR?
Malin's Other Long Term Assets of $142.30 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Drug Manufacturers company?
A good Other Long Term Assets depends on the Drug Manufacturers industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Malin and its competitors. Malin's current Other Long Term Assets is $142.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Malin stock overvalued right now?
Malin (MLLNF) has a current Other Long Term Assets of $142.30 Mil. The current Other Long Term Assets is $142.30 Mil. Malin's overall GF Score™ is 17/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For Malin (MLLNF), the current Other Long Term Assets is $142.30 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Malin Business Description

Address 50 Richmond Street South, The Lennox Building, Dublin, IRL, D02 FK02
Malin Corporation PLC is a life sciences company. Its investee companies are in science and discovery, clinical and commercial sectors. The company's approach is to create shareholder value through the selective long-term application of capital and operational expertise to private, pre-trade sale operating businesses in the life sciences industry. The company derives all of its revenue from its subsidiary. The company focuses on oncology, immunology, and genetic diseases where it believes that life science and healthcare technologies will deliver transformative treatments for patients.
17GF Score

Get the complete analysis for MLLNF

Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.40
Price